CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Artgen Biotekh PAO (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Artgen Biotekh PAO (Parent)
ul Gubkina, d. 3, k. 1, pomeshch. 1/1
Phone: +7 4956468076p:+7 4956468076 MOSCOW, 119333  Russian Federation Fax: +7 4956468076f:+7 4956468076

Business Summary
Institut Stvolovykh Kletok Cheloveka PAO (Human Stem Cells Institute OJSC or HSCI OJSC) is a Russia-based company engaged in the research and development, as well as commercialization and marketing of proprietary products and services in the areas of cell-based and gene and post-genome technologies. The Company is engaged in such projects as: Gemabank, cord blood stem cells bank; Gemascreen medical genetic diagnostics and consulting services provided by the Company domestically with the aim of early detection, treatment or prevention of inherited diseases; SPRS-therapy service a set of personalized diagnostics and treatment procedures; SynBio, which focuses on development of new medicines. In addition, the Company is a producer of Neovasculgen, a gene-therapy drug. In February 2014, it opened a biotech complex in Kyiv.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
8099 Health and allied services, not elsewhere classified

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Artur A.Isaev 51 3/23/2019 11/27/2003
General Director (CEO), Director Aleksandr V.Prikhodko 60 3/23/2019 6/28/2007
Chief Accountant Natalia A.Avanesova 57
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Angiogenezis
Human Stem Cells Institute OJSC
Icegen 2

General Information
Number of Employees: 103 (As of 9/30/2012)
Outstanding Shares: 73,452,255 (As of 6/30/2023)
Shareholders: 1,385
Fax Number: +7 4956468076


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023